Idisan (Icatibant Acetate)

Icatibant acetate is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dosage of Idisan is determined by the prescribing clinician based on the severity of the attack, patient weight, and clinical response. Healthcare professionals set the exact amount and administration schedule for each individual case.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Idisan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Idisan (icatibant acetate) is a bradykinin B2 receptor antagonist, whereas other options such as C1‑inhibitor concentrates replace deficient protein, and kallikrein inhibitors block a different step in the cascade. Idisan provides rapid symptom relief through direct receptor blockade, offering an alternative mechanism of action for patients who may not respond to or tolerate other therapies.

Idisan must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If the temperature range is exceeded, discard the product according to local regulations.

Idisan is supplied as an injectable solution for intravenous administration. The medication is given by a qualified healthcare professional, typically as a single subcutaneous injection into the abdomen or thigh, following the dosing instructions provided by the prescriber.

The most serious risks include anaphylaxis, severe hypotension, and life‑threatening angioedema of the face or throat. Patients should be monitored closely after administration, and any signs of severe allergic reaction or airway compromise require immediate medical intervention.

Idisan is contraindicated in patients with known hypersensitivity to icatibant acetate or any of the excipients in the formulation. Caution is also advised for individuals with a history of severe allergic reactions to related bradykinin‑targeting agents.